Indo US Bio-Tech Q2 Results FY27: Profit Slips to a Loss, Revenue Rs 15.05 Cr, PAT Rs -3.67 Cr
- October 30, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Indo US Bio-Tech Q2 Results FY27 were declared on 30 October 2026 on a standalone basis for the July to September 2026 quarter. Revenue fell 51.22% YoY to Rs 15.05 Cr from Rs 30.85 Cr, and the company posted a net loss of Rs 3.67 Cr against a net profit of Rs 3.45 Cr a year earlier. These quarterly results show YoY growth turning negative on both the top line and the bottom line.
Indo US Bio-Tech Ltd (INDOUS) Q2 Results FY27 announced on 30 October 2026, covering the company’s financial performance for the July to September quarter. The results date brought revenue of Rs 15.05 Cr and a PAT loss of Rs 3.67 Cr. Indo US Bio-Tech Q2 Results FY27 are based on standalone results, and revenue is down 51.22% from the same quarter last year.
Univest has built this results analysis around Indo US Bio-Tech Q2 Results, covering the financial highlights, business drivers, outlook and risks. The financial highlights come first, with revenue, Operating Profit and net profit set against the same quarter last year.
Click Here – Get Free Investment Predictions
Indo US Bio-Tech Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 15.05 Cr | Rs 30.85 Cr | -51.22% YoY |
| Operating Profit | Rs -2.6 Cr | Rs 4.16 Cr | -162.5% YoY |
| Net Profit (PAT) | Rs -3.67 Cr | Rs 3.45 Cr | -206.38% YoY |
Source: company filing for Indo US Bio-Tech Q2 Results FY27, 30 October 2026. Figures in Rs Crore, Standalone basis.
Key Takeaways from Indo US Bio-Tech Q2 Results: What Stands Out
- Revenue Rs 15.05 Cr: sales fell 51.22% YoY from Rs 30.85 Cr, roughly halving the top line against the same quarter last year.
- Net loss of Rs 3.67 Cr: against net profit of Rs 3.45 Cr a year earlier, a YoY growth figure of -206.38%.
- Operating Profit of Rs -2.6 Cr: down 162.5% YoY from Rs 4.16 Cr, so the operating line was negative before the net loss.
- Margin: Indo US Bio-Tech Q2 Results FY27 show net profit margin at -24.4% against 11.2% in the comparison quarter.
- Next step: the performance analysis below sets out how revenue, Operating Profit and net profit moved together.
Indo US Bio-Tech Q2 Results FY27: Performance Analysis
The performance analysis shows a quarter where every headline line moved lower. Revenue stood at Rs 15.05 Cr against Rs 30.85 Cr, Operating Profit was Rs -2.6 Cr against Rs 4.16 Cr, and net profit was Rs -3.67 Cr against Rs 3.45 Cr in the same quarter last year.
In Indo US Bio-Tech Q2 Results FY27, the 51.22% revenue decline was followed by a 162.5% fall in Operating Profit and a 206.38% fall in net profit, so YoY growth is negative across all three lines on the standalone results basis. The supplied data confirms these movements but does not establish the specific cause.
Subsequent filings will show how revenue, now at Rs 15.05 Cr, and the net loss of Rs 3.67 Cr compare with Indo US Bio-Tech Q2 Results; the next quarterly results are the natural checkpoint. That is where the results analysis turns to the business factors.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Return on Equity – The results analysis points to three business factors disclosed for Indo US Bio-Tech Q2 Results FY27, starting with return on equity of 15.34% in FY26. That full-year figure gives context to the quarterly results but does not by itself explain the quarter’s decline.
Per-Share Profit Growth – Annual per-share profit grew across the period from FY22 to FY26, a multi-year record that sits alongside the current quarter’s YoY decline rather than explaining it.
Compounding Rate – At 24.1% a year from FY22 to FY26, the compounding rate frames the quarter’s Rs 3.67 Cr net loss as a contrast with the longer record, which leads into the FY27 outlook.
FY27 Outlook After Indo US Bio-Tech Q2 Results
The FY27 outlook after this quarter depends on filings still to come. The results analysis uses only what the company has reported, and no management guidance is part of the supplied data, so the full-year view will form from later disclosures rather than from this single quarter alone.
Indo US Bio-Tech Q2 Results FY27 mark the second quarter of the year, and the net profit line will be read again as the third and fourth quarters are declared. Readers can track those filings through the Univest Screener. The risks flagged in the supplied data come next.
Key Risks to Watch After Indo US Bio-Tech Q2 Results FY27
Sharp Revenue Decline
Revenue declined 51.2% year on year to Rs 15.05 Cr in the latest quarter. This YoY growth reading sits at the top of Indo US Bio-Tech Q2 Results FY27 and feeds every profit line below it.
Net Loss and Narrower Margin
The company reported a net loss of Rs 3.67 Cr in the latest quarter, and net profit margin narrowed to -24.4% from 11.2% in the comparison quarter. Both readings come directly from the supplied figures.
High Debt Level
Debt is high at 0.40 times total assets in FY26. This ratio is a full-year balance sheet reading, so it adds context to the quarterly results rather than replacing them, and it closes the list of risks before the conclusion.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Indo US Bio-Tech Q2 Results FY27 show standalone revenue of Rs 15.05 Cr, an Operating Profit of Rs -2.6 Cr and a net loss of Rs 3.67 Cr. Standalone figures across the quarterly results show every line lower than the same quarter last year. Univest readers following Indo US Bio-Tech Q2 Results should consult a SEBI-registered advisor before acting on this standalone results analysis.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Indo US Bio-Tech Q2 Results FY27
What are Indo US Bio-Tech Q2 Results FY27?
Ans. Indo US Bio-Tech Q2 Results FY27 cover the July to September 2026 quarter on a standalone basis. Alongside this, revenue was Rs 15.05 Cr and net profit was Rs -3.67 Cr, as the Quick Answer summarises.
What is the results date for Indo US Bio-Tech Q2 Results FY27?
Ans. The results date for Indo US Bio-Tech was 30 October 2026, when the standalone filing was declared. This means the Financial Highlights table reflects the July to September 2026 quarter, as the opening paragraphs explain.
What revenue was reported in Indo US Bio-Tech Q2 Results FY27?
Ans. Indo US Bio-Tech reported revenue of Rs 15.05 Cr, compared with Rs 30.85 Cr a year earlier, which means the top line fell by roughly half. The Performance Analysis section covers this movement.
What net profit was reported in Indo US Bio-Tech Q2 Results FY27?
Ans. Indo US Bio-Tech Q2 Results FY27 show a net loss of Rs 3.67 Cr against net profit of Rs 3.45 Cr a year earlier, so the YoY change is -206.38%. The Key Takeaways section lists this figure.
How much YoY growth did revenue show in Indo US Bio-Tech Q2 Results FY27?
Ans. Revenue showed YoY growth of -51.22%, moving from Rs 30.85 Cr to Rs 15.05 Cr. Compared with this, Operating Profit moved by -162.5% over the same period, as the Performance Analysis section explains.
Did net profit rise or fall in Indo US Bio-Tech Q2 Results?
Ans. Net profit fell, moving from Rs 3.45 Cr a year earlier to a net loss of Rs 3.67 Cr, which means net profit margin narrowed to -24.4% from 11.2% in the comparison quarter.
What was the Operating Profit in Indo US Bio-Tech Q2 Results FY27?
Ans. Operating Profit was Rs -2.6 Cr in the quarter, compared with Rs 4.16 Cr a year earlier, a YoY change of -162.5%. The Key Takeaways section covers this directly after the Financial Highlights table.
Are Indo US Bio-Tech Q2 Results consolidated results or standalone results?
Ans. Indo US Bio-Tech Q2 Results are standalone results, as stated for the July to September 2026 quarter. Alongside this, every figure in the article, from revenue to net profit, uses the standalone basis.
What business factors shaped Indo US Bio-Tech Q2 Results FY27?
Ans. The supplied factors are return on equity of 15.34% in FY26 and per-share profit compounding at 24.1% a year from FY22 to FY26, which the Key Business Factors section places beside the quarter.
What are the key risks after Indo US Bio-Tech Q2 Results FY27?
Ans. The key risks are the 51.2% revenue decline, the net loss of Rs 3.67 Cr and debt of 0.40 times total assets in FY26, as the Key Risks section details one by one.
What is the outlook after Indo US Bio-Tech Q2 Results?
Ans. No management guidance is supplied, so the FY27 outlook depends on the third and fourth quarters still to be declared. The Outlook section makes this point using only reported figures.
Where can I find the complete Indo US Bio-Tech Q2 Results FY27 data?
Ans. The Financial Highlights table in this Univest article carries the full revenue, Operating Profit and net profit data for the quarter. Alongside this, the opening paragraphs give the declaration date and the standalone basis.
